indomethacin- indomethacin capsule, extended release
eon labs, inc. - indomethacin (unii: xxe1cet956) (indomethacin - unii:xxe1cet956) - indomethacin 75 mg - indomethacin extended-release capsules are indicated for: indomethacin extended-release is contraindicated in the following patients: risk summary use of nsaids, including indomethacin extended-release, during the third trimester of pregnancy increases the risk of premature closure of the fetal ductus arteriosus. avoid use of nsaids, including indomethacin extended-release, in pregnant women starting at 30 weeks of gestation (third trimester). there are no adequate and well-controlled studies of indomethacin extended-release in pregnant women. data from observational studies regarding potential embryofetal risks of nsaid use in women in the first or second trimesters of pregnancy are inconclusive. in the general u.s. population, all clinically recognized pregnancies, regardless of drug exposure, have a background rate of 2% to 4% for major malformations, and 15% to 20% for pregnancy loss. in animal reproduction studies retarded fetal ossification was observed with administration of indomethacin to mice and ra
indomethacin- indomethacin capsule
camber pharmaceuticals, inc. - indomethacin (unii: xxe1cet956) (indomethacin - unii:xxe1cet956) - indomethacin 25 mg - indomethacin capsules are indicated for: • moderate to severe rheumatoid arthritis including acute flares of chronic disease • moderate to severe ankylosing spondylitis • moderate to severe osteoarthritis • acute painful shoulder (bursitis and/or tendinitis) • acute gouty arthritis indomethacin capsules are contraindicated in the following patients: • known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to indomethacin or any components of the drug product [ see warnings and precautions ( 5.7, 5.9) ] • history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylactic reactions to nsaids have been reported in such patients [ see warnings and precautions ( 5.7, 5.8) ] • in the set
indometacin 100mg suppositories
a a h pharmaceuticals ltd - indometacin - suppository - 100mg
indometacin 100mg suppositories
actavis uk ltd - indometacin - suppository - 100mg
indometacin 100mg suppositories
kent pharma (uk) ltd - indometacin - suppository - 100mg
indometacin 100mg suppositories
alliance healthcare (distribution) ltd - indometacin - suppository - 100mg
indometacin 100mg suppositories
sigma pharmaceuticals plc - indometacin - suppository - 100mg
indometacin 100mg suppositories
phoenix healthcare distribution ltd - indometacin - suppository - 100mg
indometacin 100mg suppositories
de pharmaceuticals - indometacin - suppository - 100mg
indomethacin capsule, extended release
american health packaging - indomethacin (unii: xxe1cet956) (indomethacin - unii:xxe1cet956) - indomethacin 75 mg - indomethacin extended-release capsules are indicated for: - moderate to severe rheumatoid arthritis including acute flares of chronic disease - moderate to severe ankylosing spondylitis - moderate to severe osteoarthritis - acute painful shoulder (bursitis and/or tendinitis) indomethacin extended-release capsules are contraindicated in the following patients: - known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to indomethacin or any components of the drug product [see warnings and precautions ( 5.7, 5.9)] - history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylactic reactions to nsaids have been reported in such patients [see warnings and precautions ( 5.7, 5.8)] - in the setting of coronary artery bypass graft (cabg) surgery [see warnings and precautions ( 5.1)] risk summary use of nsaids, including indomethacin extended-release capsules, can cause premature clos